Background: Psoriasis is a cutaneous inflammatory condition characterized by an altered turnover of keratinocytes leading to scaly patches. Secukinumab and ixekizumab are two biologic drugs inhibiting interleukin-17. Objective: We report the first case, according to Naranjo score, of a secukinumab-induced erectile dysfunction with severe plaque psoriasis that disappeared after switching to another anti IL17 drug (ixekizumab). Methods: A 45 years old man experienced erectile dysfunction during treatment with an anti-IL17. The adverse effect appeared after 60 days of treatment with secukinumab and rapidly disappeared after discontinuation of the drug. All necessary urologic exams were carried out. Re-administration of secukinumab, due to the exacerbation of psoriasis, caused the same sexual dysfunction after 60 days. Results: Switching to ixekizumab lead to a resolution of the erectile dysfunction and a complete skin clearance. Conclusion: We describe for the first time a sexual dysfunction possibly due to secukinumab and its resolution after the switch to another similar but different drug, highlighting the potential difference between anti-IL17A drugs.

A rare case of drug-induced erectile dysfunction with secukinumab solved after switch to ixekizumab in a psoriatic patient. a case report / Dastoli, S; Iannone, Lf; Bennardo, L; Silvestri, M; Palleria, C; Nistico', S; Russo, E.; De Sarro, G. - In: CURRENT DRUG SAFETY. - ISSN 1574-8863. - 15:1(2020), pp. 69-72. [10.2174/1574886314666190726155147]

A rare case of drug-induced erectile dysfunction with secukinumab solved after switch to ixekizumab in a psoriatic patient. a case report

NISTICO' S;De Sarro G
2020

Abstract

Background: Psoriasis is a cutaneous inflammatory condition characterized by an altered turnover of keratinocytes leading to scaly patches. Secukinumab and ixekizumab are two biologic drugs inhibiting interleukin-17. Objective: We report the first case, according to Naranjo score, of a secukinumab-induced erectile dysfunction with severe plaque psoriasis that disappeared after switching to another anti IL17 drug (ixekizumab). Methods: A 45 years old man experienced erectile dysfunction during treatment with an anti-IL17. The adverse effect appeared after 60 days of treatment with secukinumab and rapidly disappeared after discontinuation of the drug. All necessary urologic exams were carried out. Re-administration of secukinumab, due to the exacerbation of psoriasis, caused the same sexual dysfunction after 60 days. Results: Switching to ixekizumab lead to a resolution of the erectile dysfunction and a complete skin clearance. Conclusion: We describe for the first time a sexual dysfunction possibly due to secukinumab and its resolution after the switch to another similar but different drug, highlighting the potential difference between anti-IL17A drugs.
2020
anti-IL17; drug-related side effects; ixekizumab; naranjo score; psoriasis; secukinumab; sexual dysfunction
01 Pubblicazione su rivista::01i Case report
A rare case of drug-induced erectile dysfunction with secukinumab solved after switch to ixekizumab in a psoriatic patient. a case report / Dastoli, S; Iannone, Lf; Bennardo, L; Silvestri, M; Palleria, C; Nistico', S; Russo, E.; De Sarro, G. - In: CURRENT DRUG SAFETY. - ISSN 1574-8863. - 15:1(2020), pp. 69-72. [10.2174/1574886314666190726155147]
File allegati a questo prodotto
File Dimensione Formato  
Dastoli_Rare-Case_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 5.42 MB
Formato Adobe PDF
5.42 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1687259
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact